Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Terrie Kellmeyer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Beta
- 1.14
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 9.19
Financials
Net Income
$-3.19MEBITDA
$-3.18MFree Cash Flow
$-13.54MEPS (diluted)
$-0.03Shares Outstanding (diluted)
91.45M+138.2%Operating Expenses
$6.53MCash & Debt
$118.33MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-46.38M | $-0.54 |
| 2024 | $0.00 | $-43.00M | $-0.52 |
| 2023 | $0.00 | $-47.51M | $-0.60 |
| 2022 | $0.00 | $-47.98M | $-0.62 |
| 2021 | $0.00 | $-37.91M | $-0.54 |
| 2020 | $0.00 | $-26.28M | $-0.45 |
| 2019 | $0.00 | $-26.29M | $-0.54 |
| 2018 | $0.00 | $-17.45M | $-0.39 |
| 2017 | $0.00 | $-13.46M | $-0.33 |
| 2016 | $0.00 | $-14.74M | $-0.42 |
| 2015 | $0.00 | $-12.11M | $-0.65 |
| 2014 | $0.00 | $-11.37M | $-1.16 |
| 2013 | $0.00 | $-3.70M | $-0.46 |
| 2012 | $0.00 | $-8.30M | $-1.18 |
Valuation
AVXLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60+20.00%Social Signal Score
Mentions (9)
- Newsnewsfilecorp.com·5d ago·Positive
Important Notice to Long-Term Shareholders of Anavex Life Sciences Corp. (AVXL): Grabar Law Office Investigates Claims on Your Behalf Philadelphia, Pennsylvania--(Newsfile Corp. - October 1, 2026) - What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Anavex Life Sciences Corp. (NASDAQ: AVXL) breached their fiduciary duties owed to the Company and its shareholders.
View source ↗ - Newsbusinesswire.com·5d ago·Negative
Securities Fraud Investigation Into Anavex Life Sciences Corp. (AVXL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ANAVEX LIFE SCIENCES CORP. (AVXL), CLICK…
View source ↗ - Newsbusinesswire.com·5d ago·Neutral
Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – AVXL LOS ANGELES--(BUSINESS WIRE)---- $AVXL--Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – AVXL.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic Changes for Company Turnaround Transcript Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic Changes for Company Turnaround Transcript
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex's Highly Qualified Director Nominees ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS' Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or “the Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cent
View source ↗ - Newsseekingalpha.com·26d ago·Neutral
Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications Prepared Remarks Transcript Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications Prepared Remarks Transcript
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
…stor Call on Wednesday, September 9, 2026, at 4:00 PM ET NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026, during which Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company's cl…
View source ↗ - Newsglobenewswire.com·42d ago·Negative
…D Submission for Fragile X Syndrome Planned for September NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today reported a business update and financial results for its third fiscal quarter ended June 30, 2026. “I am delighted to report on the continued regulatory moment…
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees Launches VoteAnavex.com to Provide Additional Information on Anavex's Director Nominees and How to Vote at the Annual Meeting of Stockholders
View source ↗
Earnings
Tue, Nov 24(in 7 weeks)
Consensus estimate $-0.11 per share
Typical surprise +18.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 28$-0.03 vs $-0.08beat
- Tue, Aug 25$0.08 vs $-0.08beat
- Mon, Feb 9$-0.06 vs $-0.10beat
- Tue, Nov 25$-0.11 vs $-0.13beat
- Tue, Aug 12$-0.16 vs $-0.13miss
- Tue, May 13$-0.13 vs $-0.16beat
Estimates and results for AVXL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AVXL officers and directors.
- Bought
- $33k
- Sold
- $10.4m
2 trades
6 trades
- Donhauser Peter D.o.bought
- Thomas Steffenbought
- Missling Christopher Usold
- Missling Christopher Usold
- Skarpelos Athanasiossold
- Missling Christopher Usold
- Boenisch Sandrasold
- Favus Elliotsold
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Jan 20, 2023 (39d later)Sell$1,001 - $15,000
- Chris Jacobshouse · NY27 · disclosed Nov 16, 2022 (35d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.